Literature DB >> 9551236

In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.

K G Naber1, M Well, K Hollauer, D Kirchbauer, W Witte.   

Abstract

Minimum inhibitory concentrations (MIC) of enoxacin, ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin and rufloxacin were determined against 400 uropathogens cultured from the urine of patients with complicated and/or hospital-acquired urinary tract infections (UTI) using an agar dilution method. The bacterial spectrum consisted of Entero-bacteriaceae (34.5%), enterococci (31.5%), staphylococci (21.2%) and non-fermenting bacteria (12.8%). Enoxacin inhibited all but one strain (Enterobacter cloacae) of Enterobacteriaceae up to an MIC of 1 mg/l (MIC90 0.25 mg/l). Regarding the total bacterial spectrum, enoxacin inhibited 54.5, 59.5, 76.0 and 83.8% up to an MIC of 1, 2, 4 and 8 mg/l, respectively. If the same breakpoint of resistance for ofloxacin according to DIN 58,940 (NCCLS), i.e. MIC > or = 4 mg/l (> or = 8 mg/l), is also taken for the other fluoroquinolones, and the 126 strains of enterococci are excluded, for which alternative agents, e.g. aminopenicillins, should be considered instead, the following resistance rates were found: ciprofloxacin and enoxacin 15.3% (15.0%), ofloxacin 17.2% (15.3%), pefloxacin 18.2% (15.3%), fleroxacin 19.3% (15.3%), lomefloxacin 19.7% (17.9%) and rufloxacin 31.8% (27.4%). According to their in vitro activity, all fluoroquinolones tested besides rufloxacin show similar rates of resistance against uropathogens and can therefore be considered good alternative agents for the treatment of complicated UTI.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551236     DOI: 10.1159/000007096

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

1.  Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria.

Authors:  P M Furneri; M Fresta; G Puglisi; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 2.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

3.  Biopsy proven acute interstitial nephritis after treatment with moxifloxacin.

Authors:  Christos Chatzikyrkou; Iyas Hamwi; Christian Clajus; Jan Becker; Carsten Hafer; Jan T Kielstein
Journal:  BMC Nephrol       Date:  2010-08-23       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.